Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.58 |
| ▸ | EGFR | P00533 | 10/20 | 0.55 |
| ▸ | ITK | Q08881 | 3/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | BLK | P51451 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482191 | 0.92 | BTK (0.68) | BTKEGFRITKSRCBLK | |
| SCHEMBL6483181 | 0.79 | BTK (0.50) | BTKEGFR | |
| SCHEMBL6493572 | 0.78 | MAOB (0.43) | EGFRITKSYKFLT1FLT4 | |
| SCHEMBL6482375 | 0.74 | EGFR (0.46) | BTKEGFRITKSYKSRC | |
| SCHEMBL6482618 | 0.74 | EGFR (0.47) | BTKEGFRITKSYKSRC | |
| SCHEMBL6483156 | 0.74 | EGFR (0.64) | BTKEGFRITKSRCBLK | |
| SCHEMBL28890182 | 0.74 | BTK (1.00) | BTKEGFRITKSRCBLK | |
| SCHEMBL6482187 | 0.73 | SCN9A (0.43) | BTKEGFRITKSYKKDR | |
| SCHEMBL6482094 | 0.72 | BTK (0.58) | BTKEGFRITKPIK3CD | |
| SCHEMBL30924679 | 0.71 | NPC1 (0.55) | BTKEGFRSYKCCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | claimed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | BTK 204/4885EGFR 228/4885ITK 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.